OPY Stock Recent News

DENVER--(BUSINESS WIRE)--CSG® (NASDAQ: CSGS) today announced that the company will present at Oppenheimer's 28th Annual Technology, Internet & Communications Conference on Monday, August 11th. The presentation will be held at 1:15 p.m. EST and will feature comments from CSG Chief Executive Officer Brian Shepherd. The conference presentation will be available via webcast here. About CSG CSG empowers companies to build unforgettable experiences, making it easier for people and businesses to c.

Coinbase Global is facing what analysts at Oppenheimer describe as an “unfavorable” setup heading into its second-quarter earnings report, with trading volumes and revenues expected to fall short of Wall Street estimates. The cryptocurrency exchange is projected to post a significant sequential drop in trading activity, despite its stock having more than doubled this year.

Veteran Dealmaker Brings More Than 25 Years of Healthcare Industry Experience NEW YORK , July 14, 2025 /PRNewswire/ -- Oppenheimer & Co. Inc. ("Oppenheimer"), a leading investment bank and wealth manager and a subsidiary of Oppenheimer Holdings (NYSE: OPY), announced today the appointment of Jon Hudson as Managing Director and Co-Head of its Healthcare Services Investment Banking team. Hudson will report to Michael Margolis, R.Ph.

Brian Schwartz, Oppenheimer analyst, joins 'Closing Bell Overtime' to talk Microsoft hitting record highs and why he is still bullish on the stock to continue higher from here.

Oppenheimer has upgraded Microsoft (NASDAQ: MSFT) to Outperform from Perform, setting a price target of $600 per share- a nearly 21% increase from the company's closing price on Tuesday. The firm believes Microsoft's long-term potential in artificial intelligence (AI) is still not fully reflected in its stock price.

CNBC's “Closing Bell” is joined by Oppenheimer's Brian Nagel to get his reaction to Nike's fiscal fourth-quarter earnings report.

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will participate in a panel discussion at the Oppenheimer Innovators in Immunology & Inflammation (I&I) Summit on June 25 in New York, NY. Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a panel titled, “Advances in Dermatology: AD and CSU” on Wednesday, June 25 at 10:.

Colin Rusch, Oppenheimer, joins 'Fast Money' to talk the future of clean energy investing after today's solar stock rout.

Nvidia (NVDA) could be set to gain from growing demand for sovereign AI, Oppenheimer analysts said, after CEO Jensen Huang toured Europe last week and announced new deals and partnerships.

Squarepoint Ops LLC bought a new position in Abeona Therapeutics Inc (NASDAQ:ABEO – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 12,028 shares of the biopharmaceutical company’s stock, valued at approximately $67,000. Other institutional investors and hedge funds have also recently made changes to their positions in the company. Adage Capital Partners GP L.L.C. boosted its holdings in shares of Abeona Therapeutics by 20.1% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,902,360 shares of the biopharmaceutical company’s stock valued at $21,736,000 after buying an additional 652,366 shares in the last quarter. 683 Capital Management LLC raised its position in Abeona Therapeutics by 17.3% in the 4th quarter. 683 Capital Management LLC now owns 791,845 shares of the biopharmaceutical company’s stock worth $4,411,000 after buying an additi